medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 2

<< Back Next >>

Rev Invest Clin 2005; 57 (2)

Liver transplantation immunosuppressors development

Olivera-Martínez MA

Language: Spanish
References: 45
Page: 237-243
PDF size: 62.77 Kb.


ABSTRACT

The history of immunosuppression is a long one. From the utilization of steroids and azathioptine in the 50’s to the design of humanized molecules that specifically block cell surface receptors. Liver transplantation is one of the procedures that benefit the most with the development of new immunosuppressors and is also one of the reasons to create a new branch in research and clinical practice: transplant medicine. It also set the standards for research in the “immunologic tolerance” field. The cornerstone in the post-liver transplant stage is the utilization of calcineurin inhibitors combined with new anti-metabolites and monoclonal antibodies. All these settings conforms a promising field in the research of new and better immunosuppressing agents.


REFERENCES

  1. Schafer DF. Liver transplantation. Looking back, looking forward. In: Transplantation of the liver. Maddrey WC, Schiff ER, Sorrell MF (Ed.). Philadelphia: Editorial Lippincott, Williams & Wilkins; 2001, p. 5-34.

  2. Starzl TE, Marchiori TL, Von Kaulla KN, et al. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963; 117: 659-76.

  3. Starzl TE. History of liver and other splachnic organ transplantation. In: Transplantation of the liver. Busuttil RW, Klintmalm GB (Ed.). Philadelphia: Editorial WB Saunders; 1996, p. 3-22.

  4. National Institutes of health consensus development conference statement: liver transplantation, June 20-23, 1983. Hepatology 1984; 4: 107S-110S.

  5. Neuberger J. Immunosupressive drugs. In: Transplantation of the liver. Maddrey WC, Schiff ER, Sorrell MF (Ed.). Philadelphia: Editorial Lippincott, Williams & Wilkins; 2001, p. 199-209.

  6. Wiesner R, Goldstein R, Donovan J, et al. The impact of cyclosporine dose and level on acute rejection and patient graft survival in liver transplant recipients. Liver Transplant Surg 1998; 4: 34-41.

  7. Dagher L, Burroughs AK. Liver transplantation: prevention and treatment of rejection. In: Evidence Based Gastroenterology and Hepatology. McDonald J, Burroughs A, Feagan B (Ed.). Editorial BMJ Books London; 1999, p. 491-511.

  8. Wenger RM. Structures of cyclosporine and its metabolites. Transplant Proc 1990; 22: 1104-9.

  9. Fruhman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosupression. FASEB 1994; 8: 391-400.

  10. Diliz HS, Olivera MA, Kershenobich D, Mercado MA, Orozco H. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant patients. Transplant Proc 1996; 28: 3348-50.

  11. Calne RY, White DJ. The use of cyclosporin A in clinical organ grafting. Ann Surg 1982; 196: 330-7.

  12. Keown PA. Molecular and clinical therapeutics of cyclosporine in transplantation. In: Immunosupression in transplantation. Ginns LC, Cosimi AB, Morris PJ (Ed.). USA: Editorial Blackwell Science Malden; 1999, p. 1-12.

  13. Herbert MF, Davis CL, Limaye AP, Kowdley KV, Carithers RL Jr. Liver transplantation: long-term post-transplant management. In: Transplantation of the liver. Maddrey WC, Schiff ER, Sorrell MF (Ed.). Philadelphia: Editorial Lippincott, Williams & Wilkins; 2001, p. 392-404.

  14. Simposio Satélite de la International Liver Transplantation Society (ILTS) auspiciado por Novartis pharmaceutical and Toronto University. Cyclosporine C2 monitoring: improved patient management, improved results. Exposición en ILTS annual meeting Chicago 11 Junio 2002.

  15. Levy G, Villamil F, Samuel D, et al. Results of a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in the novo liver transplantation. Transplantation 2004; 77: 1632-8.

  16. Denton MD, Magee C, Sayegh MH. Immunosuppressive strategies in organ transplantation. Curr Opin Organ Transplant 1998; 3: 175-82.

  17. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II Fermentation, isolation and characterization. J Antibiot 1975; 28: 727-32.

  18. Senel F, Kahan BD. New small molecule immunosuppressive agents. In: Immunosupression in transplantation. Ginns LC, Cosimi AB, Morris PJ (Ed.). USA: Editorial Blackwell Science Malden; 1999, p. 67-84.

  19. Kirchner G, Roechte F, Winkler M, Deters M, Kaever V, Meier-Wiedenbach I, Manns M. Steady state pharmacokinetics of RAD (everolimus) in transplant recipients. Gastroenterology. Sólo disponible en AOD (CD) DDW 2002, abstract T-1427.

  20. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-17.

  21. O’Grady JG. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Liver Transplant 2004; 17-22.

  22. Reding R, Gras J, Sokal E, et al. Steroid-free liver transplantation in children. Lancet 2003; 35: 3032-4.

  23. Fisher RA, Ham JM, Marcos A, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998; 66: 1616-21.

  24. Herrero JI, Quiroga J, Sangro B, et al. Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus. Transplant Proc 2003; 35: 1877-9.

  25. Herbert MF, Ascher NL, Lake JR, et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67: 707-12.

  26. Vincenti F. Targeting the interleukin-2 receptor in clinical renal transplantation. Graft 1999; 2: 56-61.

  27. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107-13.

  28. Nashan B, Schlitt HJ, Schwinzer R, et al. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 1996; 61: 546-54.

  29. Wilson CH, Brook NR, Gok MA, et al. Prospective randomized trial of the use of Daclizumab in renal transplantation using kidneys from in on heart beating donors. Ann Transplant 2004; 9: 29-30.

  30. Saxer SB, Jonson AR, Lally AL, Shick L, Katz E. Tacrolimus with steroids withdrawal-Is it the gold standard for immunosupression in liver transplantation? Liver Transplant 2002; 8: (abst) C-9.

  31. Innocenti F, Hepp J, Humeres R, et al. Rapid steroid taper and neoral monotherapy in liver transplantation in Chile: A step in the right direction? Transplant Proc 2004; 36: 1675-6.

  32. Figueras J, Llado L, Xiol X, Vázquez S, Lama C, Ramos E, Baliellas C, Fabregat J, Castellote J, Rafecas A, Casanovas T, Torrás J, Gómez N, Jaurrieta E. Preliminary results of a prospective randomized trial of the safety and efficacy of steroid-free immunosupression after liver transplantation. Liver Transplant 2002; 8: (abst) C-34.

  33. Kneteman N, Bigman D, Al-Saghier M, Meeberg G, Shapiro J, Bain V, Ma M, Gutfreund K, Wong W. Liver transplantation with a steroid-free, low toxicity immunosuppressive protocol. Liver Transplant 2002; 8: (abst) C-34.

  34. Margarit C, Bilbao I, Pou L, Allende H, Hidalgo E, Charco R. Steroid-free immunosupression with tacrolimus after liver transplantation for hepatitis C viral cirrhosis. Liver Transplant 2002; 8: (abst) C-35.

  35. Greig P, Lilly L, Scudamore C, et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transplant 2003; 9: 587-95.

  36. Angelico M, Lionetti R, Manzia TM, Casarelli F, Ciceroni C, Zazza S, Di Paolo D, Tisone G. Complete withdrawal of immunosupression in liver transplant recipients with recurrent hepatitis C: safety and short-term outcome. Liver Transplant 2002; 8: (abst) C-16.

  37. Fisher A, Seguel J, De la Torre A, Wilson D, Korogodski M, Koneru B. Basiliximab induction in liver transplantation. Liver Transplant 2002; 8: (abst) C-8.

  38. Zanotelli ML, Greizler AL, Brandao AB, Marroni CA, Cantisani GP. Basiliximab as an induction immunosupression in liver transplantation. Liver Transplant 2002; 8: (abst) C-8.

  39. Olivera MA, López A, Plata JJ, Galindo E, Chan C, Leal-Villalpando P, Mercado MA, Orozco H. Inducing immunosupression with basiliximab in liver transplantation. J Hepatol 2002; 36 (abst) S: 192, 678.

  40. Varo E, López A, Tome S, Delgado M, Conde R, Bustamante M, Rivero C, Martínez J, Otero E, Castroagudin J. Use of low-tacrolimus, basiliximab and steroids in liver transplant recipients with postoperative acute renal failure. Liver Transplant 2002; 8: (abst) C-7.

  41. Pfitzman R, Klupp J, Langrehr JM, Settmacher U, Steinmueller T, Neuhaus R, Neuhaus P. Reduction of calcineurin-inhibitor induced side effects with additional immunosupression with mycophenolate mofetil after liver transplantation. Liver Transplant 2002; 8: (abst) C-7.

  42. Langrehr JM, Klupp J, Pfitzman R, Steinmueller T, Settmacher U, Neuhaus P. Rescue therapy with mycophenolate mofetil after orthotopic liver transplantation. Liver Transplant 2002; 8: (abst) C-34.

  43. Heffron T, Smallwood GA, Davis L, Martínez E, Stieber A. Immunosupressive protocol for renal sparing: sirolimus vs. mycophenolate. Liver Transplant 2002; 8: (abst) C-33.

  44. Wiesner R, Klintmalm G, McDiarmid S, Neuhaus P. Sirolimus decreases acute rejection rates in de novo orthotopic liver transplantation recipients. Liver Transplant 2002; 8: (abst) C-16.

  45. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY-720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61: 200-5.




2020     |     www.medigraphic.com